ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) will present clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study, at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. The study evaluates evorpacept in combination with azacitidine and venetoclax for treating acute myeloid leukemia (AML). The poster presentation is scheduled for December 12, 2022, highlighting promising clinical responses from evorpacept across various hematologic and solid malignancies.

Positive

• Evorpacept shows promising clinical responses in AML and other malignancies.
• Presentation at a major hematology conference enhances visibility and credibility.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the Company will be presenting clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (“AML”) at the 64^th American Society of Hematology (“ASH”) Annual Meeting held December 10-13, 2022 in New Orleans, Louisiana.

The accepted abstract is listed below and is now available online on the ASH website: http://www.hematology.org/Annual-Meeting/Abstracts/.

Poster Presentation Details

Title: Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Presentation Date and Location: Monday, December 12, 2022, 6:00pm – 8:00pm CT, Ernest N. Morial Convention Center, Hall D

Publication Number: 4076
    

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

FAQ

What is the purpose of the ASPEN-05 study involving ALXO?

The ASPEN-05 study evaluates the combination of evorpacept, azacitidine, and venetoclax for treating acute myeloid leukemia (AML).

When and where will ALXO present their clinical data?

ALX Oncology will present their clinical data on December 12, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

What is evorpacept and its significance for ALXO?

Evorpacept is ALX Oncology's lead product candidate, a CD47-blocking therapeutic showing potential in treating multiple solid tumor indications and hematologic malignancies.

What results will ALXO present at the ASH Annual Meeting?

ALXO will present results from the Phase 1a dose escalation part of the ASPEN-05 study involving evorpacept.

What is the expected market impact of ALXO's study results?

Positive results from the ASPEN-05 study could enhance ALXO's market position and attract further investment in its clinical programs.